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BACKGROUND: Serum cytokine concentrations may reflect inflammatory processes occurring during the development of colorectal
neoplasms. Flavonols, bioactive compounds found in plant-based foods and beverages, may inhibit colorectal neoplasms partly by
attenuating inflammation.
METHODS: Using logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) to investigate the association
between serum concentrations of interleukin (IL)1b, 2, 8, 10, 12p70, granulocyte macrophage colony stimulating factor, interferon-g,
and tumour necrosis factor-a, measured over time, flavonol intake, estimated from a flavonol database used in conjunction with a
food frequency questionnaire, and adenoma recurrence in 872 participants from the intervention arm of the Polyp Prevention Trial.
RESULTS: Decreased IL-2 concentration during the trial increased the risk of any adenoma recurrence (4th vs 1st quartile, OR¼1.68,
95% CI¼1.13–2.49), whereas decreased IL-1b or IL-10 reduced the risk of advanced adenoma recurrence (OR¼0.37, 95%
CI¼0.15–0.94; OR¼0.39, 95% CI¼0.15–0.98, respectively). Individuals with flavonol intake above the median (29.7mg per day)
and decreased cytokine concentrations had the lowest risk of advanced adenoma recurrence.
CONCLUSION: Overall, no consistent associations were observed between serum cytokine profile and colorectal adenoma recurrence;
however, decreased cytokine concentrations during high flavonol consumption may indicate prevention of colorectal neoplasms.
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Growing evidence suggests that inflammation is important in
carcinogenesis, including colorectal cancer (Lin and Karin, 2007).
Cytokine concentrations in either serum or tumours may be
useful indicators of inflammation and risk of neoplastic changes
(Pellegrini et al, 2006; Cui and Florholmen, 2008). Compared with
healthy individuals, serum cytokine concentrations of interleukin-
2 (IL-2) are reported to be lower, whereas concentrations of IL-8,
IL-10, IL-12, granulocyte macrophage colony stimulating factor
(GMCSF), interferon (IFN)-g, and tumour necrosis factor (TNF)a
are higher in individuals with colorectal adenomas in some studies
(Berghella et al, 1997; Mroczko et al, 2001; Galizia et al, 2002;
Ordemann et al, 2002; Contasta et al, 2003; Roselli et al, 2003;
Kaminska et al, 2005; Kim et al, 2008).
Flavonols are a flavonoid subgroup of bioactive polyphenols that
are present in many plant-based foods and beverages (Chun et al,
2007; Bobe et al, 2008). The literature and our own studies suggest
that flavonols are one of the flavonoid subgroups most effective in
decreasing the risk of advanced and high-risk colorectal adenoma
recurrence (Bobe et al, 2008, 2010) and colorectal cancer (Rossi et al,
2006; Theodoratou et al, 2007). Several human studies indicate that
flavonols have anti-inflammatory properties (Chun et al, 2008; Boots
et al,2 0 0 9 ;B o b eet al,2 0 1 0 ) ,w h i c hm a yb eo n eo ft h es e v e r a l
molecular mechanisms by which flavonols may inhibit the growth of
colorectal neoplasms. The aims of this study were to examine
whether serum concentrations of IL-1b, IL-2, IL-8, IL-10, IL-12p70,
GMCSF, IFNg,a n dT N F a were associated with flavonol intake or
could predict colorectal adenoma recurrence. In addition, we
investigated whether a predicted protective effect of flavonol intake
might be mediated by changes in serum cytokine concentrations.
MATERIALS AND METHODS
Study design and outcome
The Polyp Prevention Trial (PPT) was a 4-year multi-centre,
randomised, nutritional intervention trial to evaluate whether
colorectal adenoma recurrence can be inhibited by increasing
fibre, fruit, and vegetable consumption and decreasing the
proportion of fat in the diet. The study has previously been
described in detail (Schatzkin et al, 2000; Lanza et al, 2001).
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histologically confirmed colorectal adenoma identified by com-
plete colonoscopy in the 6 months before study entry. Of the 1905
participants who completed the trial by undergoing a colonoscopy
at the end of year 4, 958 were in the intervention arm. Our study
included the 872 participants in the intervention arm with
available dietary data for any of the first 3 years of the trial and
serum from baseline (T0) and either from year 1 (T1) or 3 (T3).
Two pathologists independently examined all lesions for histo-
logical features and degree of atypia. Adenoma recurrence was
defined as: any (X1 adenoma, n¼348), high risk (X3 adenomas
or X1 advanced adenoma, n¼100), or advanced (X1 adenoma of
X1cm in size, having X25% villous component, or exhibiting
high-grade dysplasia, n¼49). The institutional review boards of
the National Cancer Institute and each participating centre
approved the study, and all participants provided written informed
consent.
Lifestyle and flavonol data
At T0 and at each of the annual follow-up visits (T1, T2, T3, and
T4), participants were asked to complete an interviewer-adminis-
tered questionnaire about demographics, family history, and use of
medication or supplements (including name and dosage), as well
as a self-administered food frequency questionnaire (FFQ) that
was reviewed with a certified nutritionist. The FFQ was specifically
designed and validated to accurately measure fat, fibre, fruit, and
vegetable consumption (Block et al, 1990). Relative to 24h dietary
recall and 4-day food record data, the FFQ slightly overestimated
fat and underestimated fibre, fruit and vegetable intake, and had
acceptable correlations of macronutrients and micronutrients
(Caan et al, 1999; Lanza et al, 2001). The average flavonol intake
for the first 3 years of the trial was estimated using 55 of
the 119 questions on the FFQ using the 2007 flavonoid database
(U.S. Department of Agriculture, 2007) and was calculated as the
sum of isorhamnetin, kaempferol, myricetin, and quercetin.
Serum data
At each annual visit, participants provided an overnight fasting
blood sample, the serum from which was stored at  701C until
analysis. Among the 872 participants, 23 and 69 had no available
samples at T1 and T3, respectively. Serum concentrations of IL-1b,
IL-2, IL-8, IL-10, IL-12p70, GMCSF, IFNg, and TNFa were
measured at T0, T1, and T3 by the Clinical Support Laboratory
of SAIC Frederick, Inc. (Frederick, MD, USA) using a commer-
cially available multiplex 96-well enzyme-linked immunoabsorbent
assay kit (MS6000 Human Pro-Inflammatory 9-Plex Ultra-Sensitive
Kit K11007; Meso Scale Diagnostics, Gaithersburg, MD, USA)
on a Sector Imager 6000 according to the manufacturer’s
recommendation (Meso Scale Diagnostics). Study samples were
run with two pooled serum samples and three assay specific
standards in duplicate and the average of the duplicate was used.
Fewer than 1% of the samples were below the detection limit, and
the interassay coefficient of variation (CV) was below 15%.
Statistical analyses
Statistical analyses were performed using SAS, version 9.1 (SAS,
Inc., Cary, NC, USA) software. Baseline characteristics, average
dietary intake for the first 3 years of the trial, and serum cytokine
concentrations were evaluated by adenoma recurrence at T4 (no vs
any, high-risk, or advanced adenoma recurrence) using Wilcoxon
rank-sum test for continuous variables and Fisher’s exact test for
categorical variables and are shown as medians and interquartile
ranges (IQRs). Spearman’s correlation coefficients between serum
cytokine concentrations were calculated. The association between
serum cytokine concentrations and flavonol consumption during
the first 3 years of the trial was evaluated with the Kruskal–Wallis
test and multiple linear regression models.
We defined trial cytokine concentrations as the geometric mean
of T1 and T3. Cytokine concentration changes during the trial were
defined as the geometric mean of T1 and T3 minus the baseline
values. The association between cytokine changes and colorectal
adenoma recurrence was estimated by odds ratios (ORs) and 95%
confidence intervals (CIs) using logistic regression. A trend test
was performed using the median values of each quartile as a
continuous variable in a logistic regression model. The median
values of both flavonol intake and cytokine changes were used as
cutoffs (pmedian, 4median) to examine the combined effect of
flavonol intake and cytokine changes on colorectal adenoma
recurrence. Potential confounders (listed in Table 1) were added to
the models in a stepwise manner and remained in the model if they
changed the association by 410%, were associated with both study
variables, and had a w
2 P-value p0.20. All P-values corresponded
to two-sided tests and were considered to be significant when
Pp0.05.
RESULTS
At the end of the 4-year trial, 40% of participants had at least 1
adenoma, 11% had high-risk adenoma, and 6% had an advanced
adenoma recurrence (Table 1). Compared with baseline, flavonol
consumption increased two-fold from 14.6 to 29.7mg per day
during the first 3 years of the trial (Bobe et al, 2010). Adenoma
recurrence was more common in men, older individuals, and
individuals that ate a greater percentage of calories from fat during
the first 3 years of the trial, and less common in women who used
hormone therapy. Individuals who had recurrence of a high-risk or
advanced adenoma consumed less fibre (limited to individuals
with a high-risk adenoma), fruits and vegetables, flavonols, and
dry beans (Table 1). Serum concentrations of IL-1b, IL-2, IL-8,
IL-10, GMCSF, IFNg, and TNFa, either at baseline, during the first
3 years of the trial, or from baseline to during the trial, were not
associated with colorectal adenoma recurrence; with the exception
that IL-12p70 was lower at baseline in individuals with high-risk
and advanced adenoma recurrence than in individuals with no
adenoma recurrence (Table 1; data not shown). Of the eight serum
cytokines measured, only IFNg concentrations differed across
quartiles of flavonol intake; individuals in the lowest flavonol
intake quartile had higher IFNg concentrations compared with
individuals in the higher 3 flavonol intake quartiles (Table 2).
No statistically significant associations were observed between
serum cytokine concentrations during the trial (defined as the
mean of concentration at T1 and T3) and adenoma recurrence
(data not shown). In contrast, a decrease in IL-2 concentrations
during the trial (the mean trial level minus the baseline
concentration) was associated with increased risk of any adenoma
recurrence (lowest vs highest quartile of change in cytokine
concentration: OR¼1.68, 95% CI¼1.13–2.49), whereas a decrease
in IL-1b or IL-10 reduced the risk of advanced adenoma
recurrence (OR¼0.37, 95% CI¼0.15–0.94 and OR¼0.39, 95%
CI¼0.15–0.98, respectively; Table 3).
Individuals with above median flavonol intake and equal or
below median change in serum cytokines concentrations had the
lowest risk of advanced adenoma recurrence for all cytokines
investigated but not all were statistically significant (Figure 1).
Compared with individuals with equal or below median flavonol
intake and above median serum cytokine concentrations, the risk
reduction was statistically significant for changes in concentrations
of IL-1b, IL-10, IL-12p70, GMCSF, IFNg, or TNFa (Figure 1;
Supplementary Table S1). Similar results were observed for the
combined effect of flavonol intake and serum cytokine concentra-
tions at baseline (less significant effect) or during the trial
(Supplementary Tables S2 and S3).
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Previously, we reported that serum concentrations of IL-6 may be
a potential risk indicator for advanced and high-risk adenoma
recurrence; furthermore, dietary flavonols decrease elevated IL-6
concentrations and decrease the risk of advanced and high-risk
adenoma recurrence (Bobe et al, 2010). In the current study, we
examined serum concentrations of eight cytokines (IL-1b, IL-2,
IL-8, IL-10, IL-12p70, GMCSF, IFNg, and TNFa) in relation to
flavonol intake and colorectal adenoma recurrence and found none
to be associated with flavonol intake and with colorectal adenoma
recurrence. Only IFNg concentrations varied significantly across
flavonol intake quartiles. Serum cytokine concentrations were not
associated with colorectal adenoma recurrence with the exception
that a decrease in IL-2 concentrations during the trial increased the
risk of any adenoma recurrence, and a decrease in IL-1b or IL-10
reduced the risk of advanced adenoma recurrence. Individuals
with high flavonol intake (above 29.7mg per day) and a decrease in
serum concentrations of six of the eight measured cytokines had
the lowest risk of advanced adenoma recurrence. Thus, our results
suggest that there is not a consistent association between serum
cytokine profile and colorectal adenoma recurrence; however,
Table 1 Proportions and medians (IQRs) of participant characteristics in the intervention arm of the Polyp Prevention Trial by adenoma recurrence
at T4 (n¼872)
Adenoma recurrence (T4)
None Any High risk Advanced
Characteristics
Median
(IQR) or %
Median
(IQR) or % P-value
a
Median
(IQR) or % P-value
a
Median
(IQR) or % P-value
a
Sample size (%) 524 (60) 348 (40) 100 (11) 49 (6)
Baseline (T0)
Gender (% male) 64 70 0.05 76 0.02 69 0.53
Race (% Caucasian) 88 90 0.58 90 0.73 86 0.64
Education (% phigh school) 22 27 0.11 31 0.07 31 0.21
Family history of colorectal cancer (% yes)
b 27 26 0.88 30 0.46 27 1.00
Smoker (% current) 11 14 0.21 18 0.07 14 0.48
NSAID use (% yes)
c 35 37 0.67 33 0.65 31 0.54
Supplement use (% yes)
c 45 43 0.68 38 0.23 37 0.30
Hormone therapy (% yes)
c 13 9 0.05 6 0.04 8 0.38
Age (years) 60.0 (52.0–67.0) 64.0 (57.0–70.0) o0.0001 66.0 (58.0–71.0) o0.0001 66.0 (60.0–71.0) 0.0006
Body mass index (kgm
 2) 27.5 (24.8–30.3) 27.6 (25.1–30.6) 0.36 28.3 (25.4–31.1) 0.06 28.6 (26.1–32.4) 0.01
Physical activity (hours per week)
d 8.50 (4.00–15.1) 8.46 (3.82–16.0) 0.93 8.27 (3.33–13.1) 0.21 7.16 (2.67–12.0) 0.19
Serum cytokines (pgml
 1)
Interleukin-1b 0.36 (0.22–0.60) 0.37 (0.22–0.63) 0.88 0.37 (0.21–0.72) 0.95 0.34 (0.19–0.62) 0.42
Interleukin-2 0.72 (0.34–1.45) 0.69 (0.37–1.60) 0.61 0.66 (0.42–1.54) 0.50 0.83 (0.48–1.60) 0.26
Interleukin-8 10.4 (7.81–13.7) 10.2 (8.09–14.1) 0.58 10.8 (8.47–16.3) 0.14 11.0 (9.05–15.2) 0.19
Interleukin-10 3.27 (2.16–5.81) 3.22 (2.07–6.07) 0.48 3.23 (2.14–4.49) 0.26 2.80 (2.03–4.00) 0.08
Interleukin-12p70 3.16 (1.69–7.69) 2.99 (1.47–7.16) 0.35 2.61 (1.36–5.64) 0.04 2.22 (1.31–4.84) 0.05
GMCSF 0.83 (0.41–1.90) 0.70 (0.36–1.89) 0.40 0.61 (0.33–1.44) 0.08 0.61 (0.36–1.07) 0.12
Interferon-g 1.29 (0.85–2.37) 1.33 (0.83–2.28) 0.91 1.29 (0.87–2.39) 0.60 1.23 (0.86–1.84) 0.87
Tumour necrosis factor a 8.36 (6.80–10.1) 8.22 (6.79–10.3) 0.77 8.57 (7.00–10.6) 0.09 8.28 (6.76–10.0) 0.97
Trial (T1,2,3)
e
Dietary intake
Alcohol (g per day) 0.90 (0.00–8.76) 0.96 (0.00–8.26) 0.51 0.98 (0.00–5.63) 0.42 0.98 (0.00–4.93) 0.24
Energy (1000kcal per day) 1.78 (1.52–2.09) 1.79 (1.54–2.07) 1.00 1.80 (1.56–1.99) 0.92 1.82 (1.60–1.99) 0.95
Fat (% kcal per day) 22.4 (18.5–26.6) 22.9 (19.7–28.1) 0.03 25.1 (20.9–30.0) 0.0003 27.4 (22.2–30.6) 0.0002
Fibre (g per day) 32.1 (24.0–40.8) 30.9 (22.8–39.0) 0.13 29.4 (21.6–36.2) 0.01 29.4 (21.5–37.7) 0.08
Fruits and vegetables (servings per day) 5.72 (4.43–7.15) 5.65 (4.48–6.99) 0.54 5.24 (4.36–6.56) 0.03 4.98 (4.06–6.03) 0.01
Flavonols (mg per day) 29.7 (21.4–40.8) 29.7 (21.0–38.9) 0.59 25.4 (16.2–36.1) 0.005 21.0 (15.0–30.1) 0.0002
Dry beans (g per day) 31.2 (15.3–54.6) 30.3 (14.4–49.5) 0.26 23.0 (8.79–42.1) 0.005 14.0 (7.37–35.2) 0.0001
Serum cytokines (pgml
 1)
Interleukin-1b 0.37 (0.24–0.62) 0.36 (0.23–0.59) 0.43 0.41 (0.26–0.68) 0.28 0.43 (0.25–0.68) 0.36
Interleukin-2 0.81 (0.37–1.58) 0.75 (0.35–1.41) 0.30 0.85 (0.45–1.58) 0.83 0.86 (0.51–1.65) 0.49
Interleukin-8 10.6 (8.15–15.5) 10.9 (8.36–14.7) 0.89 11.0 (8.52–16.1) 0.54 11.0 (8.98–15.2) 0.45
Interleukin-10 3.20 (2.22–5.66) 3.14 (2.10–5.56) 0.32 3.23 (2.01–4.91) 0.38 3.08 (1.87–5.66) 0.39
Interleukin-12p70 3.13 (1.66–7.09) 2.81 (1.48–6.92) 0.16 2.61 (1.47–5.29) 0.04 2.28 (1.46–5.27) 0.06
GMCSF 0.83 (0.43–1.76) 0.74 (0.36–1.81) 0.20 0.56 (0.34–1.42) 0.06 0.57 (0.35–1.32) 0.22
Interferon-g 1.39 (0.93–2.32) 1.37 (0.91–2.01) 0.36 1.48 (1.00–2.41) 0.39 1.55 (1.18–2.00) 0.23
Tumour necrosis factor a 8.15 (6.88–9.78) 8.22 (6.99–9.98) 0.52 8.28 (7.27–11.0) 0.05 8.22 (7.00–10.0) 0.58
Abbreviations: GMCSF¼granulocyte macrophage colony stimulating factor; IQR¼interquartile range; NSAID¼non-steroidal anti-inflammatory drug.
aAll comparisons against
the no adenoma recurrence group. P-values for differences in proportions were calculated using Fisher’s exact test. P-values for differences in medians were calculated using
Wilcoxon rank-sum test.
bFamily history of colorectal cancer was defined as having X1 first-degree relative with colorectal cancer at baseline.
cRegular dietary supplement use
was defined as taking supplement X1 weekly. Regular medication use, including NSAIDs, was defined as taking medication X1 monthly. Hormone replacement therapy included
both unopposed estrogen and estrogen/progestin combinations.
dPhysical activity was defined as self-reported time typically spent for any type of moderate or vigorous physical
activity.
eT1,2,3: mean values of the first 3 years of the trial for dietary variables and geometric mean of years 1 and 3 cytokine values.
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consumption (429.7mg per day) may indicate a lower risk for
advanced colorectal adenoma.
Chronic inflammation, involving many pro- as well as anti-
inflammatory cytokines, is one of the many mechanisms reported
to promote colorectal carcinogenesis (Lin and Karin, 2007).
Similar to our findings, lower serum concentrations of IL-2
have been reported in colorectal adenoma and cancer patients
vs healthy individuals (Berghella et al, 1997; Contasta et al, 2003).
IL-2 is a lymphokine that enhances the growth and cytotoxic
response of activated T cells and is used as an adjuvant treatment
of solid tumours (Grande et al, 2006). We anticipated an increase
in serum IL-1b in individuals with advanced adenoma recurrence,
although Roselli et al (2003) did not observe differences in serum
IL-1b concentrations between healthy and colorectal adenoma or
cancer patients, because IL-1b initiates the pro-inflammatory
cascade and is necessary for tumour invasion and metastasis (Apte
et al, 2006; Krelin et al, 2007). Furthermore, the gene and protein
expression of IL-1b is higher in colorectal adenoma and adeno-
carcinoma relative to normal colon tissue (Miki et al, 2002;
Schetter et al, 2009). The role of IL-10 in colorectal carcinogenesis
is complex as it can alternately promote and inhibit carcinogenesis
(Moore et al, 2001; Lin and Karin, 2007; Uronis et al, 2009), and
both increased and decreased IL-10 gene or protein expression
have been found in tumour tissue (Miki et al, 2002; Csiszar et al,
2004; Schetter et al, 2009; Stanilov et al, 2009). Compared with
healthy individuals, colorectal cancer patients have significantly
higher IL-10 concentrations but individuals with adenomas do not
(Berghella et al, 1997; Ordemann et al, 2002; Contasta et al, 2003;
Stanilov et al, 2009), suggesting that IL-10 may be a better risk
indicator for more advanced tumour stages.
Although we did not find associations for IL-8, IL-12p70,
GMCSF, IFNg, and TNFa and adenoma recurrence, they may serve
as risk indicators for more advanced tumour stages. Elevated
concentrations of IL-8, TNFa, IL-12 (a heterodimer consisting of
IL-12p40 and IL-12p70), GMCSF, and IFNg in blood have been
reported in colorectal cancer patients in some but not all studies
(Berghella et al, 1996, 1997, 2002; Mroczko et al, 2001, 2007;
Contasta et al, 2003; Roselli et al, 2003; Kaminska et al, 2005;
Schetter et al, 2009; Stanilov et al, 2009). Low baseline values, large
CVs, and a limited dynamic range in most human samples
combined with smaller increases in cytokine concentrations in
blood in early vs later stages of colorectal neoplasia may limit the
potential of IL-8, TNFa, IL-12p70, GMCSF, and IFNg as risk
indicators for colorectal cancer prevention, although higher
concentrations of TNFa in blood have been observed in colorectal
adenoma patients compared with healthy individuals (Berghella
et al, 1996; Roselli et al, 2003; Kim et al, 2008).
Flavonols are naturally occurring bioactive polyphenols found
in various plant-based foods and beverages, especially in apples,
beans, onions, and tea (Chun et al, 2007; Bobe et al, 2008), that
may attenuate secretion of pro-inflammatory cytokines in humans
(Chun et al, 2008; Boots et al, 2009; Egert et al, 2010). There are
multiple molecular mechanisms by which flavonols may attenuate
inflammatory processes, including inhibiting the activity of
dendritic and mast cells (Park et al, 2008; Huang et al, 2010),
attenuating nitric oxide production (Wang et al, 2006) and path-
ways induced by cyclooxygenase and lipoxygenase (Wang et al,
2006; Bednar et al, 2007; Lee et al, 2010a), inducing the expression
of non-steroidal anti-inflammatory drug activated gene-1 (Lim
et al, 2007), and decreasing the activity of phopholipase A2
(Moon et al, 2008), peroxisome proliferator activated receptor g
(Lian et al, 2008), and nuclear factor kB (Ruiz and Haller, 2006;
Park et al, 2008). In the United States, the median flavonol intake is
estimated to be B10–12mg per day, with a range between 0 and
40mg, the primary dietary flavonols being quercetin (70% of total
flavonols), kaempferol (16%), myricetin (12%), and isorhamnetin
(2%) (Peterson JJ, personal communication). Previously, we
reported that high flavonol intake (430mg per day) may decrease
serum IL-6 and the incidence of high-risk and advanced adenoma
recurrence in the PPT (Bobe et al, 2010). In the current study, we
observed that high flavonol consumption (421mg per day)
may also decrease serum IFN g. Flavonol supplementation studies
do not usually observe changes in blood cytokines except
in individuals with elevated baseline values combined with an
inflammatory challenge (Nieman et al, 2007; Boots et al, 2008,
2009). Studies in cell culture (Nair et al, 2002; Min et al, 2007;
Bandyopadhyay et al, 2008; Okoko and Oruambo, 2009) and
animal models (Kwon et al, 2005; Camuesco et al, 2006) often use
an inflammatory challenge to measure the flavonol-induced
attenuation of cytokine secretion and gene expression. Thus,
flavonols may primarily benefit individuals at increased inflam-
mation risk, or flavonol-induced changes in inflammatory markers
may be too small to be detected when cytokine concentrations are
within the normal dynamic range.
We observed the lowest risk for advanced adenoma recurrence
with high flavonol intake (430mg per day) and a concurrent
decrease in serum cytokine concentrations. In addition to their
Table 2 Medians (IQRs) of serum cytokine concentrations by flavonol intake during the trial (n¼872)
Flavonol intake quartiles (mg per day)
b
Cytokine
a Q1: o21.1 Q2: 21.1–29.6 Q3: 29.7–40.0 Q4: 440.0
(pgml
 1) Median (IQR) Median (IQR) Median (IQR) Median (IQR) P non-param.
c P for trend
d
Sample size 218 218 218 218
Interleukin-1b 0.41 (0.26–0.70) 0.36 (0.23–0.61) 0.35 (0.23–0.51) 0.35 (0.22–0.62) 0.14 0.09
Interleukin-2 0.80 (0.38–1.65) 0.74 (0.30–1.41) 0.780 (0.39–1.26) 0.77 (0.37–1.66) 0.69 0.28
Interleukin-8 10.8 (8.42–14.7) 11.0 (8.72–16.0) 10.5 (7.85–15.0) 10.5 (7.95–15.2) 0.62 0.90
Interleukin-10 3.41 (2.26–6.11) 3.02 (2.07–4.96) 3.15 (2.15–6.40) 3.27 (2.19–5.58) 0.53 0.81
Interleukin-12p70 3.17 (1.70–7.85) 2.73 (1.48–5.53) 3.06 (1.70–7.25) 3.02 (1.48–7.84) 0.15 0.92
GMCSF 0.82 (0.43–1.78) 0.70 (0.38–1.48) 0.82 (0.38–2.34) 0.83 (0.41–2.05) 0.35 0.74
Interferon-g 1.61 (1.13–2.64) 1.20 (0.78–2.06) 1.37 (0.91–2.15) 1.28 (0.89–1.98) 0.0003 0.03
Tumour necrosis factor a 8.06 (6.68–10.2) 8.52 (7.05–10.2) 8.02 (6.93–9.71) 8.15 (6.95–9.65) 0.46 0.90
Abbreviations: GMCSF¼granulocyte macrophage colony stimulating factor; IQR¼interquartile range.
aGeometric mean of years 1 and 3 cytokine values (Trial (T1,3)).
bParticipants were grouped in quartiles (Q1–Q4) by mean flavonol intake during the first 3 trial years.
cP-values for differences in medians among the flavonol intake quartiles
were calculated based on the Kruskal–Wallis test.
dMedian concentrations of each flavonol quartile were used to determine P for trend of the cytokine concentrations using a
multiple regression model adjusting for age tertiles (o58, 58–66, 466 years), sex, average BMI (o25, 25.0–29.9, X30kgm
 2), smoking status, and average energy intake
(continuous) during the first 3 trial years. Individuals in the lowest flavonol intake quartile had higher interferon-g concentrations than individuals in the three higher flavonol intake
quartiles, while not differing among each other.
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inhibit carcinogenesis through several other pathways. Flavonols
can decrease various forms of DNA damage (Duthie and Dobson,
1999; Wilms et al, 2005); they have anti-mutagenic properties (Ruf
et al, 2003; Gupta et al, 2010), stabilise the helical structure of DNA
(Kanakis et al, 2007), and enhance DNA repair (Min and Ebeler,
2009). Furthermore, flavonols can scavenge reactive oxygen
species (Kim et al, 2006; Wang et al, 2006), bind metals (Guo
et al, 2007), decrease lipid peroxidation (Lee et al, 2010c), inhibit
the activity of phase I procarcinogen activating enzymes (Si et al,
2009; Lam et al, 2010; Tiong et al, 2010), and induce the expression
of phase II carcinogen detoxification enzymes (Lam et al, 2010)
and antioxidant proteins (Kimura et al, 2009). In the tumour
promotion and progression stage, flavonols inhibit transformation
of pre-carcinogenic cells (Ichimatsu et al, 2007; Lee et al, 2008) and
proliferation of cancer cells (Richter et al, 1999; Kim et al, 2005) by
inducing cell cycle arrest and apoptosis (Choi et al, 2008; Jeong
et al, 2009). Furthermore, flavonols inhibit tumour angiogenesis
and invasiveness by repressing expression of the angiogenesis-
promoting vascular endothelial growth factors (Kim et al, 2006;
Luo et al, 2009; Lee et al, 2010b) and invasion-promoting matrix
metalloproteinases, respectively (Vijayababu et al, 2006; Lin et al,
Table 3 Association between quartiles of change
a in serum cytokine concentrations from baseline to the levels measured during the trial (mean
of T1 and T3) and colorectal adenoma recurrence in the intervention arm of the Polyp Prevention Trial (n¼872)
Adenoma recurrence (T4)
Cytokine None
Any High risk Advanced
(pgml
 1) n (%) n (%) OR (95% CI)
b n (%) OR (95% CI)
b n (%) OR (95% CI)
b
Interleukin-1b
Q1:40.16 136 (62.7) 81 (37.3) 1.00 29 (13.4) 1.00 18 (8.3) 1.00
Q2: 0.02–0.16 133 (61.0) 85 (39.0) 1.05 (0.71–1.56) 22 (10.1) 0.71 (0.38–1.32) 9 (4.1) 0.48 (0.20–1.13)
Q3:  0.13–0.01 128 (58.7) 90 (41.3) 1.15 (0.78–1.71) 31 (14.2) 1.07 (0.59–1.92) 15 (6.9) 0.82 (0.39–1.76)
Q4:o 0.13 127 (58.0) 92 (42.0) 1.17 (0.79–1.73) 18 (8.2) 0.57 (0.30–1.11) 7 (3.2) 0.37 (0.15–0.94)
P for trend
c 0.40 0.18 0.06
Interleukin-2
Q1:40.41 142 (65.4) 75 (34.6) 1.00 25 (11.5) 1.00 13 (6.0) 1.00
Q2: 0.07–0.41 132 (60.6) 86 (39.4) 1.22 (0.82–1.82) 21 (9.6) 0.87 (0.46–1.67) 11 (5.0) 0.90 (0.38–2.12)
Q3:  0.30–0.06 133 (61.0) 85 (39.0) 1.17 (0.79–1.74) 26 (11.9) 1.05 (0.56–1.94) 11 (5.0) 0.88 (0.37–2.07)
Q4:o 0.30 117 (53.4) 102 (46.6) 1.68 (1.13–2.49) 28 (12.8) 1.33 (0.72–2.45) 14 (6.4) 1.31 (0.58–2.95)
P for trend
c 0.01 0.31 0.52
Interleukin-8
Q1:42.74 137 (63.1) 80 (36.9) 1.00 21 (9.7) 1.00 8 (3.7) 1.00
Q2: 0.25–2.74 128 (58.7) 90 (41.3) 1.19 (0.80–1.76) 20 (9.2) 0.97 (0.49–1.90) 12 (5.5) 1.55 (0.60–3.99)
Q3:  2.02–0.24 124 (56.9) 94 (43.1) 1.30 (0.88–1.93) 30 (13.8) 1.53 (0.81–2.87) 15 (6.9) 2.06 (0.83–5.13)
Q4:o 2.02 135 (61.6) 84 (38.4) 1.00 (0.67–1.48) 29 (13.2) 1.31 (0.70–2.45) 14 (6.4) 1.65 (0.66–4.14)
P for trend
c 0.83 0.27 0.24
Interleukin-10
Q1:40.57 135 (62.2) 82 (37.8) 1.00 27 (12.4 1.00 18 (8.3) 1.00
Q2:  0.03–0.57 127 (58.3) 91 (41.7) 1.11 (0.75–1.65) 26 (11.9) 0.95 (0.51–1.75) 12 (5.5) 0.66 (0.30–1.47)
Q3:  0.88 to  0.04 133 (61.0) 85 (39.0) 1.02 (0.69–1.52) 24 (11.0) 0.84 (0.45–1.56) 12 (5.5) 0.61 (0.28–1.36)
Q4:o 0.88 129 (58.9) 90 (41.1) 1.16 (0.78–1.72) 23 (10.5) 0.86 (0.46–1.60) 7 (3.2) 0.39 (0.15–0.98)
P for trend
c 0.50 0.62 0.04
Interleukin-12p70
Q1:40.68 137 (63.1) 80 (36.9) 1.00 24 (11.1) 1.00 15 (6.9) 1.00
Q2:  0.08–0.68 126 (57.8) 92 (42.2) 1.17 (0.79–1.73) 32 (14.7) 1.27 (0.69–2.34) 16 (7.3) 1.04 (0.48–2.26)
Q3:  1.03 to  0.09 128 (58.7) 90 (41.3) 1.15 (0.78–1.70) 24 (11.0) 0.98 (0.52–1.86) 9 (4.1) 0.63 (0.26–1.54)
Q4:o 1.03 133 (60.7) 86 (39.3) 1.10 (0.74–1.63) 20 (9.1) 0.84 (0.43–1.63) 9 (4.1) 0.60 (0.25–1.45)
P for trend
c 0.78 0.43 0.21
Granulocyte macrophage colony stimulating factor
Q1:40.22 137 (63.1) 80 (36.9) 1.00 25 (11.5) 1.00 16 (7.4) 1.00
Q2: 0.01–0.22 122 (56.0) 96 (44.0) 1.31 (0.89–1.94) 27 (12.4) 1.15 (0.62–2.14) 15 (6.9) 1.02 (0.47–2.21)
Q3:  0.29–0.00 134 (61.5) 84 (38.5) 1.04 (0.70–1.55) 30 (13.8) 1.15 (0.62–2.10) 12 (5.5) 0.72 (0.32–1.62)
Q4:o 0.29 131 (59.8) 88 (40.2) 1.20 (0.81–1.78) 18 (8.2) 0.78 (0.40–1.54) 6 (2.7) 0.41 (0.15–1.09)
P for trend
c 0.51 0.42 0.06
Interferon-g
Q1:40.57 134 (61.5) 84 (38.5) 1.00 26 (11.9) 1.00 16 (7.3) 1.00
Q2: 0.08–0.57 131 (60.4) 87 (39.6) 0.95 (0.64–1.41) 27 (12.4) 0.82 (0.44–1.53) 13 (6.0) 0.63 (0.28–1.42)
Q3:  0.39–0.07 132 (60.6) 86 (39.4) 0.97 (0.65–1.43) 25 (11.5) 0.84 (0.45–1.56) 11 (5.0) 0.58 (0.26–1.34)
Q4:o 0.39 127 (58.0) 92 (42.0) 1.13 (0.77–1.67) 22 (10.0) 0.84 (0.44–1.58) 9 (4.1) 0.56 (0.23–1.34)
P for trend
c 0.49 0.61 0.18
Tumour necrosis factor a
Q1:40.87 129 (59.4) 88 (40.6) 1.00 21 (9.7) 1.00 12 (5.5) 1.00
Q2: 0.03–0.87 131 (60.1) 87 (39.9) 0.97 (0.66–1.44) 29 (13.3) 1.39 (0.73–2.62) 15 (6.9) 1.33 (0.58–3.01)
Q3:  0.90–0.02 128 (58.7) 90 (41.3) 1.05 (0.71–1.54) 27 (12.4) 1.38 (0.72–2.61) 12 (5.5) 1.08 (0.46–2.56)
Q4:o 0.90 136 (62.1) 83 (37.9) 0.88 (0.60–1.31) 23 (10.5) 1.01 (0.53–1.96) 10 (4.6) 0.81 (0.33–1.97)
P for trend
c 0.60 0.96 0.56
Abbreviations: CI¼confidence interval; OR¼odds ratio.
aChange in cytokine values is defined as difference between the geometric mean value of years 1 and 3 and baseline.
bMultivariate OR and 95% CI models were adjusted for age tertiles (o58, 58–66, 466 years), sex, average BMI (o25, 25.0–29.9, X30kgm
 2), and current smoking status
during the first 3 trial years.
cMedian concentrations of each quartile were used to determine P for trend for the change in cytokine concentrations.
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decrease in cytokine concentrations may be, at least in part, a
result of flavonols inhibiting adenoma progression rather than a
direct effect on cytokine expression and secretion.
One of the strengths of this study is the detailed end point
information, which included complete colonoscopies and histolo-
gic characterisation of all lesions by two pathologists, decreasing
the risk of misclassification. A second strength is the prospective
and repeated collection of dietary exposure. The modified FFQ
used in the PPT was specifically developed to accurately measure
high fruit and vegetable consumption (Block et al, 1990; Lanza
et al, 2001) and was linked to the recently released validated USDA
flavonoid database (U.S. Department of Agriculture, 2007). The
accuracy of the FFQ was further improved as registered dieticians
reviewed the FFQ with participants (Caan et al, 1999). A third
strength is the repeated collection of serum, which allowed us to
look at changes during, what may be, early stages of colorectal
carcinogenesis.
Limitations of the study include the fact that the PPT is a study
of individuals with a history of adenomas, most of whom were
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Figure 1 Association between the combination of high (429.7mg per day) or low (p29.7mg per day) flavonol intake during the trial and change in
serum concentration of cytokines (defined as the geometric mean of T1 and T3 minus baseline values) on advanced colorectal adenoma recurrence among
participants in the intervention arm of the Polyp Prevention Trial. The cutoff values for an increase or decrease in serum cytokine concentrations area s
follows (in pgml
 1): DIL-1b: 40.01 (increase), p0.01 (decrease); DIL-2: 40.06 (increase), p0.06 (decrease); DIL-8: 40.24 (increase), p0.24 (decrease);
DIL-10: 4 0.04 (increase), p 0.04 (decrease); DIL-12p70: 4 0.09 (increase), p 0.09 (decrease); DGMCSF: 40.00 (increase), p0.00 (decrease);
DIFNg: 40.07 (increase), p0.07 (decrease); TNFa: 40.02 (increase), p0.02 (decrease). The reference group is the combination of low flavonol intake and
increase in cytokine concentrations.
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Random as well as systematic measurement error related to the
dietary assessment, the flavonoid database, and the participants’
knowledge of the expected dietary patterns may be present and
could bias risk estimates. The low abundance, high CVs, daily
fluctuations, short half-lives, lack of specificity for location,
strength and type of inflammation, and the limited dynamic
ranges of cytokines in most human serum samples could partly
explain the inconsistent results for serum cytokines as markers of
colorectal neoplasia and limit the usefulness of many cytokines as
biomarkers. Observed differences may have arisen by chance as
participants were not randomly assigned to a specific flavonol diet,
the number of cases of advanced adenoma recurrence was small,
and multiple cytokines were tested for multiple outcomes (multiple
testing). However, the consistent lower risk of advanced adenoma
recurrence with decreasing cytokine concentration during high
flavonol consumption is unlikely due to chance. Besides flavonols,
other flavonoid subgroups, such as anthocyanins, flavan-3-ols,
flavones, and isoflavonoids, have cancer-protective and anti-
inflammatory properties (Yoon and Baek, 2005; Ferguson and
Philpott, 2007; Wang and Stoner, 2008). We focused on flavonols
because they were the flavonoid subgroup most protective against
advanced adenoma recurrence in the PPT (Bobe et al, 2008); the
intake ranges of other flavonoid subgroups in the PPT may be too
limited to detect associations.
In conclusion, our results suggest that a decrease in cytokine
concentrations during high flavonol consumption may serve as a
risk indicator for colorectal cancer prevention. Verification of
these results in other prospective cohorts with high quality and
repeated dietary and serum cytokine measures is needed to clarify
the role of serum cytokines as indicators of a chemopreventive
response to dietary flavonols.
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